Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Rifón Roca JJ, Cassaday RD, Böll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Díaz MT, Vucinic V, González-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernández-Rivas JM, Gordon PR, Brüggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. Jabbour E, et al. Among authors: katlinskaya y. Am J Hematol. 2024 Apr;99(4):586-595. doi: 10.1002/ajh.27227. Epub 2024 Feb 5. Am J Hematol. 2024. PMID: 38317420
Spatial characterization and quantification of CD40 expression across cancer types.
Bates KM, Vathiotis I, MacNeil T, Ahmed FS, Aung TN, Katlinskaya Y, Bhattacharya S, Psyrri A, Yea S, Parkes A, Sadraei NH, Roychoudhury S, Rimm DL, Gavrielatou N. Bates KM, et al. Among authors: katlinskaya y. BMC Cancer. 2023 Mar 9;23(1):220. doi: 10.1186/s12885-023-10650-7. BMC Cancer. 2023. PMID: 36894898 Free PMC article.
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
Katz DA, Morris JD, Chu MP, David KA, Thieblemont C, Morley NJ, Khan SS, Viardot A, Martín García-Sancho A, Rodríguez-García G, Bastos-Oreiro M, Lee ST, Kormany W, Chen Y, Wong HL, Anderson AA, Katlinskaya Y, Avilion AA, Dai T, González-Barca E. Katz DA, et al. Among authors: katlinskaya y. Leuk Lymphoma. 2022 Sep;63(9):2063-2073. doi: 10.1080/10428194.2022.2064981. Epub 2022 May 3. Leuk Lymphoma. 2022. PMID: 35503708 Free article. Clinical Trial.
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.
Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY. Ortiz A, et al. Among authors: katlinskaya yv. Cancer Cell. 2019 Jan 14;35(1):33-45.e6. doi: 10.1016/j.ccell.2018.12.001. Cancer Cell. 2019. PMID: 30645975 Free PMC article.
Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments.
Yu JW, Bhattacharya S, Yanamandra N, Kilian D, Shi H, Yadavilli S, Katlinskaya Y, Kaczynski H, Conner M, Benson W, Hahn A, Seestaller-Wehr L, Bi M, Vitali NJ, Tsvetkov L, Halsey W, Hughes A, Traini C, Zhou H, Jing J, Lee T, Figueroa DJ, Brett S, Hopson CB, Smothers JF, Hoos A, Srinivasan R. Yu JW, et al. Among authors: katlinskaya y. PLoS One. 2018 Nov 2;13(11):e0206223. doi: 10.1371/journal.pone.0206223. eCollection 2018. PLoS One. 2018. PMID: 30388137 Free PMC article.
Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.
Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR, Puré E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, Rui H, Fuchs SY. Katlinski KV, et al. Among authors: katlinskaya yv. Cancer Cell. 2017 Feb 13;31(2):194-207. doi: 10.1016/j.ccell.2017.01.004. Cancer Cell. 2017. PMID: 28196594 Free PMC article.
PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.
Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke KA, Paredes MC, Yoshida A, Qie S, Zhang G, Chajewski OS, Wu L, Majsterek I, Herlyn M, Fuchs SY, Diehl JA. Pytel D, et al. Among authors: katlinskaya yv. PLoS Genet. 2016 Dec 15;12(12):e1006518. doi: 10.1371/journal.pgen.1006518. eCollection 2016 Dec. PLoS Genet. 2016. PMID: 27977682 Free PMC article.
A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon.
Zhang KJ, Yin XF, Yang YQ, Li HL, Xu YN, Chen LY, Liu XJ, Yuan SJ, Fang XL, Xiao J, Wu S, Xu HN, Chu L, Katlinski KV, Katlinskaya YV, Guo RB, Wei GW, Wang DC, Liu XY, Fuchs SY. Zhang KJ, et al. Among authors: katlinskaya yv. Clin Cancer Res. 2017 Apr 15;23(8):2038-2049. doi: 10.1158/1078-0432.CCR-16-1386. Epub 2016 Sep 28. Clin Cancer Res. 2017. PMID: 27683179 Free PMC article.
14 results